HR 9 REGULATORY RISK ASSESSMENT COMPLIANCE WOULD ADD ABOUT $20 MIL. TO FDA SPENDING ON PREMARKET ACTIVITIES, CBO ESTIMATES; HRG HAS SIMILAR PROJECTIONS
This article was originally published in The Gray Sheet
Executive SummaryFDA spending on premarket regulatory activities would increase by about $20 mil. a year if the agency is subjected to the risk assessment requirements under Title III of the "Job Creation and Wage Enhancement Act" (HR 9), the Congressional Budget Office estimates in scoring of the Commerce Committee version of the bill released Feb. 15.
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
HBW Market News: FTC Ends Another Supplement Scam, Australia Win For ChromaDex, GOED Report, Herbalife
Herbalife opens 9,200 square-foot training facility in China; GOED's latest annual market report, covering 2017-2018, is available; ChromaDex has two-tear exclusivity for nicotinamide riboside chloride in Australia; and A.S. Research arthritis claims for Synovia end in FTC settlement.
Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.